Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 89

1.

Dual Inhibition of GSK3β and CDK5 Protects the Cytoskeleton of Neurons from Neuroinflammatory-Mediated Degeneration In Vitro and In Vivo.

Reinhardt L, Kordes S, Reinhardt P, Glatza M, Baumann M, Drexler HCA, Menninger S, Zischinsky G, Eickhoff J, Fröb C, Bhattarai P, Arulmozhivarman G, Marrone L, Janosch A, Adachi K, Stehling M, Anderson EN, Abo-Rady M, Bickle M, Pandey UB, Reimer MM, Kizil C, Schöler HR, Nussbaumer P, Klebl B, Sterneckert JL.

Stem Cell Reports. 2019 Jan 31. pii: S2213-6711(19)30017-7. doi: 10.1016/j.stemcr.2019.01.015. [Epub ahead of print]

2.

Gasdermin D plays a vital role in the generation of neutrophil extracellular traps.

Sollberger G, Choidas A, Burn GL, Habenberger P, Di Lucrezia R, Kordes S, Menninger S, Eickhoff J, Nussbaumer P, Klebl B, Krüger R, Herzig A, Zychlinsky A.

Sci Immunol. 2018 Aug 24;3(26). pii: eaar6689. doi: 10.1126/sciimmunol.aar6689.

PMID:
30143555
3.

TRPC4/TRPC5 channels mediate adverse reaction to the cancer cell cytotoxic agent (-)-Englerin A.

Cheung SY, Henrot M, Al-Saad M, Baumann M, Muller H, Unger A, Rubaiy HN, Mathar I, Dinkel K, Nussbaumer P, Klebl B, Freichel M, Rode B, Trainor S, Clapcote SJ, Christmann M, Waldmann H, Abbas SK, Beech DJ, Vasudev NS.

Oncotarget. 2018 Jul 3;9(51):29634-29643. doi: 10.18632/oncotarget.25659. eCollection 2018 Jul 3.

4.

Identification of Noncatalytic Lysine Residues from Allosteric Circuits via Covalent Probes.

Bongard J, Lorenz M, Vetter IR, Stege P, Porfetye AT, Schmitz AL, Kaschani F, Wolf A, Koch U, Nussbaumer P, Klebl B, Kaiser M, Ehrmann M.

ACS Chem Biol. 2018 May 18;13(5):1307-1312. doi: 10.1021/acschembio.8b00101. Epub 2018 Apr 16.

PMID:
29658704
5.

Sustainability in humanitarian surgery during medical short-term trips (MSTs): feasibility of inguinal hernia repair in rural Nigeria over 6 years and 13 missions.

Oehme F, Fourie L, Beeres FJ, Ogbaji S, Nussbaumer P.

Hernia. 2018 Jun;22(3):491-498. doi: 10.1007/s10029-018-1758-4. Epub 2018 Mar 31.

PMID:
29605842
6.

Dynarrestin, a Novel Inhibitor of Cytoplasmic Dynein.

Höing S, Yeh TY, Baumann M, Martinez NE, Habenberger P, Kremer L, Drexler HCA, Küchler P, Reinhardt P, Choidas A, Zischinsky ML, Zischinsky G, Nandini S, Ledray AP, Ketcham SA, Reinhardt L, Abo-Rady M, Glatza M, King SJ, Nussbaumer P, Ziegler S, Klebl B, Schroer TA, Schöler HR, Waldmann H, Sterneckert J.

Cell Chem Biol. 2018 Apr 19;25(4):357-369.e6. doi: 10.1016/j.chembiol.2017.12.014. Epub 2018 Jan 27.

PMID:
29396292
7.

Interaction of KRas4B protein with C6-ceramide containing lipid model membranes.

Li L, Dwivedi M, Erwin N, Möbitz S, Nussbaumer P, Winter R.

Biochim Biophys Acta Biomembr. 2018 May;1860(5):1008-1014. doi: 10.1016/j.bbamem.2018.01.016. Epub 2018 Jan 31.

PMID:
29357287
8.

Identification of an (-)-englerin A analogue, which antagonizes (-)-englerin A at TRPC1/4/5 channels.

Rubaiy HN, Seitz T, Hahn S, Choidas A, Habenberger P, Klebl B, Dinkel K, Nussbaumer P, Waldmann H, Christmann M, Beech DJ.

Br J Pharmacol. 2018 Mar;175(5):830-839. doi: 10.1111/bph.14128. Epub 2018 Jan 25.

9.

Na+ entry through heteromeric TRPC4/C1 channels mediates (-)Englerin A-induced cytotoxicity in synovial sarcoma cells.

Muraki K, Ohnishi K, Takezawa A, Suzuki H, Hatano N, Muraki Y, Hamzah N, Foster R, Waldmann H, Nussbaumer P, Christmann M, Bon RS, Beech DJ.

Sci Rep. 2017 Dec 5;7(1):16988. doi: 10.1038/s41598-017-17303-3.

10.

Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer.

Lücking U, Scholz A, Lienau P, Siemeister G, Kosemund D, Bohlmann R, Briem H, Terebesi I, Meyer K, Prelle K, Denner K, Bömer U, Schäfer M, Eis K, Valencia R, Ince S, von Nussbaum F, Mumberg D, Ziegelbauer K, Klebl B, Choidas A, Nussbaumer P, Baumann M, Schultz-Fademrecht C, Rühter G, Eickhoff J, Brands M.

ChemMedChem. 2017 Nov 8;12(21):1776-1793. doi: 10.1002/cmdc.201700447. Epub 2017 Oct 16.

11.

Identification of Two Secondary Ligand Binding Sites in 14-3-3 Proteins Using Fragment Screening.

Sijbesma E, Skora L, Leysen S, Brunsveld L, Koch U, Nussbaumer P, Jahnke W, Ottmann C.

Biochemistry. 2017 Aug 1;56(30):3972-3982. doi: 10.1021/acs.biochem.7b00153. Epub 2017 Jul 21.

12.

Picomolar, selective, and subtype-specific small-molecule inhibition of TRPC1/4/5 channels.

Rubaiy HN, Ludlow MJ, Henrot M, Gaunt HJ, Miteva K, Cheung SY, Tanahashi Y, Hamzah N, Musialowski KE, Blythe NM, Appleby HL, Bailey MA, McKeown L, Taylor R, Foster R, Waldmann H, Nussbaumer P, Christmann M, Bon RS, Muraki K, Beech DJ.

J Biol Chem. 2017 May 19;292(20):8158-8173. doi: 10.1074/jbc.M116.773556. Epub 2017 Mar 21.

13.

Development of Pyridazinone Chemotypes Targeting the PDEδ Prenyl Binding Site.

Murarka S, Martín-Gago P, Schultz-Fademrecht C, Al Saabi A, Baumann M, Fansa EK, Ismail S, Nussbaumer P, Wittinghofer A, Waldmann H.

Chemistry. 2017 May 2;23(25):6083-6093. doi: 10.1002/chem.201603222. Epub 2016 Nov 3.

PMID:
27809361
14.

Identification of pyrazolopyridazinones as PDEδ inhibitors.

Papke B, Murarka S, Vogel HA, Martín-Gago P, Kovacevic M, Truxius DC, Fansa EK, Ismail S, Zimmermann G, Heinelt K, Schultz-Fademrecht C, Al Saabi A, Baumann M, Nussbaumer P, Wittinghofer A, Waldmann H, Bastiaens PI.

Nat Commun. 2016 Apr 20;7:11360. doi: 10.1038/ncomms11360.

15.

The Evolving Role of the Medicinal Chemist.

Lawton G, Nussbaumer P.

Prog Med Chem. 2016;55:193-226. doi: 10.1016/bs.pmch.2015.11.001. Epub 2016 Jan 15. Review. No abstract available.

PMID:
26852936
16.

Professional translational research: a new hybrid paradigm in early drug discovery.

Nussbaumer P, Klebl B.

Future Med Chem. 2015;7(14):1879-89. doi: 10.4155/fmc.15.124. Epub 2015 Sep 30.

17.

Medicinal Chemists of the 21(st) Century--Who Are We and Where to Go?

Nussbaumer P.

ChemMedChem. 2015 Jul;10(7):1133-9. doi: 10.1002/cmdc.201500133. Epub 2015 Apr 29.

PMID:
25924977
18.

Structure guided design and kinetic analysis of highly potent benzimidazole inhibitors targeting the PDEδ prenyl binding site.

Zimmermann G, Schultz-Fademrecht C, Küchler P, Murarka S, Ismail S, Triola G, Nussbaumer P, Wittinghofer A, Waldmann H.

J Med Chem. 2014 Jun 26;57(12):5435-48. doi: 10.1021/jm500632s. Epub 2014 Jun 11.

PMID:
24884780
19.

Evaluation of a romifidine constant rate infusion protocol with or without butorphanol for dentistry and ophthalmologic procedures in standing horses.

Marly C, Bettschart-Wolfensberger R, Nussbaumer P, Moine S, Ringer SK.

Vet Anaesth Analg. 2014 Sep;41(5):491-7. doi: 10.1111/vaa.12174. Epub 2014 May 17.

PMID:
24835127
20.

Design, synthesis and biological evaluation of 3,5-disubstituted 2-amino thiophene derivatives as a novel class of antitumor agents.

Romagnoli R, Baraldi PG, Lopez-Cara C, Salvador MK, Preti D, Tabrizi MA, Balzarini J, Nussbaumer P, Bassetto M, Brancale A, Fu XH, Yang-Gao, Li J, Zhang SZ, Hamel E, Bortolozzi R, Basso G, Viola G.

Bioorg Med Chem. 2014 Sep 15;22(18):5097-109. doi: 10.1016/j.bmc.2013.12.030. Epub 2013 Dec 24.

21.

Cheminformatics at the interface of medicinal chemistry and proteomics.

Koch U, Hamacher M, Nussbaumer P.

Biochim Biophys Acta. 2014 Jan;1844(1 Pt A):156-61. doi: 10.1016/j.bbapap.2013.05.010. Epub 2013 May 21. Review.

PMID:
23707564
22.

Lower shedding of strongylid eggs by Warmblood horses with recurrent airway obstruction compared to unrelated healthy horses.

Bründler P, Frey CF, Gottstein B, Nussbaumer P, Neuhaus S, Gerber V.

Vet J. 2011 Nov;190(2):e12-5. doi: 10.1016/j.tvjl.2010.12.029. Epub 2011 Feb 10.

PMID:
21315626
23.

S1P receptor mediated activity of FTY720 phosphate mimics.

Högenauer K, Hinterding K, Nussbaumer P.

Bioorg Med Chem Lett. 2010 Mar 1;20(5):1485-7. doi: 10.1016/j.bmcl.2010.01.118. Epub 2010 Jan 28.

PMID:
20153186
24.

Estimating least-developed countries' vulnerability to climate-related extreme events over the next 50 years.

Patt AG, Tadross M, Nussbaumer P, Asante K, Metzger M, Rafael J, Goujon A, Brundrit G.

Proc Natl Acad Sci U S A. 2010 Jan 26;107(4):1333-7. doi: 10.1073/pnas.0910253107. Epub 2010 Jan 5.

25.

4,5,6-Trisubstituted piperidinones as conformationally restricted ceramide analogues: synthesis and evaluation as inhibitors of sphingosine and ceramide kinases and as NKT cell-stimulatory antigens.

Mathew T, Cavallari M, Billich A, Bornancin F, Nussbaumer P, De Libero G, Vasella A.

Chem Biodivers. 2009 Oct;6(10):1688-715. doi: 10.1002/cbdv.200900045.

PMID:
19842132
26.

Synthesis and evaluation of sphingolipid analogues: modification of the hydroxy group at C(1) of 7-oxasphingosine, and of the hydroxy group at C(1) and the amide group of 7-oxaceramides.

Mathew T, Billich A, Cavallari M, Bornancin F, Nussbaumer P, De Libero G, Vasella A.

Chem Biodivers. 2009 May;6(5):705-24. doi: 10.1002/cbdv.200900013.

PMID:
19479849
27.

Synthesis of 7-aza- and 7-thiasphingosines, and evaluation of their interaction with sphingosine kinases and with T-cells.

Mathew T, Billaud C, Billich A, Cavallari M, Nussbaumer P, De Libero G, Vasella A.

Chem Biodivers. 2009 May;6(5):725-38. doi: 10.1002/cbdv.200900039.

PMID:
19479838
28.

Structure-activity relationship studies on a novel class of antiproliferative agents derived from Lavendustin A. Part I: Ring A modifications.

Nussbaumer P, Winiski AP.

Bioorg Med Chem. 2008 Aug 15;16(16):7552-60. doi: 10.1016/j.bmc.2008.07.039. Epub 2008 Jul 20.

PMID:
18678497
29.

[Genetics of recurrent airway obstruction (RAO)].

Gerber V, Swinburne JE, Blott SC, Nussbaumer P, Ramseyer A, Klukowska-Rötzler J, Dolf G, Marti E, Burger D, Leeb T.

Dtsch Tierarztl Wochenschr. 2008 Jul;115(7):271-5. Review. German.

PMID:
18672738
30.

Phosphorylation by sphingosine kinase 2 is essential for in vivo potency of FTY720 analogues.

Högenauer K, Billich A, Pally C, Streiff M, Wagner T, Welzenbach K, Nussbaumer P.

ChemMedChem. 2008 Jul;3(7):1027-9. doi: 10.1002/cmdc.200800037. No abstract available.

PMID:
18383466
31.

Regulation and traffic of ceramide 1-phosphate produced by ceramide kinase: comparative analysis to glucosylceramide and sphingomyelin.

Boath A, Graf C, Lidome E, Ullrich T, Nussbaumer P, Bornancin F.

J Biol Chem. 2008 Mar 28;283(13):8517-26. Epub 2007 Dec 16.

32.

Medicinal chemistry aspects of drug targets in sphingolipid metabolism.

Nussbaumer P.

ChemMedChem. 2008 Apr;3(4):543-51. Review. No abstract available.

PMID:
18061920
33.

An efficient, one-pot synthesis of various ceramide 1-phosphates from sphingosine 1-phosphate.

Nussbaumer P, Hornillos V, Ghobrial M, Ullrich T.

Chem Phys Lipids. 2008 Feb;151(2):125-8. Epub 2007 Nov 9.

PMID:
18039471
34.
35.

Synthesis and immobilization of erythro-C14-omega-aminosphingosine-1-phosphate as a potential tool for affinity chromatography.

Ullrich T, Ghobrial M, Peters C, Billich A, Guerini D, Nussbaumer P.

ChemMedChem. 2008 Feb;3(2):356-60.

PMID:
18000941
36.

Synthesis of borondipyrromethene (BODIPY)-labeled sphingosine derivatives by cross-metathesis reaction.

Peters C, Billich A, Ghobrial M, Högenauer K, Ullrich T, Nussbaumer P.

J Org Chem. 2007 Mar 2;72(5):1842-5. Epub 2007 Jan 24.

PMID:
17249735
37.

Richter's hernia after colonoscopy: a rare complication.

Fluri P, Keller W, Nussbaumer P.

Gastrointest Endosc. 2006 Jan;63(1):177-8. No abstract available.

PMID:
16377345
38.

NBD-labeled derivatives of the immunomodulatory drug FTY720 as tools for metabolism and mode of action studies.

Ettmayer P, Baumruker T, Guerini D, Mechtcheriakova D, Nussbaumer P, Streiff MB, Billich A.

Bioorg Med Chem Lett. 2006 Jan 1;16(1):84-7. Epub 2005 Oct 19.

PMID:
16236505
39.

One-step labelling of sphingolipids via a scrambling cross-metathesis reaction.

Nussbaumer P, Ettmayer P, Peters C, Rosenbeiger D, Högenauer K.

Chem Commun (Camb). 2005 Oct 28;(40):5086-7. Epub 2005 Sep 14.

PMID:
16220179
40.

Percutaneous embolization of renal arteriovenous fistula.

Sendi P, Toia D, Nussbaumer P.

Vasa. 2005 Aug;34(3):207-10.

PMID:
16184844
41.

[Acute vascular occlusion of the upper extremity after blunt trauma].

Pecinska N, Nussbaumer P, Furrer M.

Vasa. 2005 Aug;34(3):201-2. German.

PMID:
16184842
42.

Steroid sulfatase inhibitors: their potential in the therapy of breast cancer.

Nussbaumer P, Billich A.

Curr Med Chem Anticancer Agents. 2005 Sep;5(5):507-28. Review.

PMID:
16178776
43.

[First experience with a critical incident reporting system in surgery].

Missbach-Kroll A, Nussbaumer P, Kuenz M, Sommer C, Furrer M.

Chirurg. 2005 Sep;76(9):868-74; discussion 875. German.

PMID:
15977018
44.

[The role of video-thoracoscopy in thoracic surgery].

Nussbaumer P, Furrer M.

Ther Umsch. 2005 Feb;62(2):77-84. Review. German.

PMID:
15756915
45.

N-Acyl arylsulfonamides as novel, reversible inhibitors of human steroid sulfatase.

Lehr P, Billich A, Wolff B, Nussbaumer P.

Bioorg Med Chem Lett. 2005 Feb 15;15(4):1235-8.

PMID:
15686949
46.

6-[2-(adamantylidene)-hydroxybenzoxazole]-O-sulfamate, a steroid sulfatase inhibitor for the treatment of androgen- and estrogen-dependent diseases.

Billich A, Meingassner JG, Nussbaumer P, Desrayaud S, Lam C, Winiski A, Schreiner E.

J Steroid Biochem Mol Biol. 2004 Sep;92(1-2):29-37.

PMID:
15544928
47.

2-(1-adamantyl)-4-(thio)chromenone-6-carboxylic acids: potent reversible inhibitors of human steroid sulfatase.

Horvath A, Nussbaumer P, Wolff B, Billich A.

J Med Chem. 2004 Aug 12;47(17):4268-76.

PMID:
15293998
48.

Steroid sulfatase inhibitors.

Nussbaumer P, Billich A.

Med Res Rev. 2004 Jul;24(4):529-76. Review.

PMID:
15170594
49.

Confocal fluorescence detection expanded to UV excitation: the first continuous fluorimetric assay of human steroid sulfatase in nanoliter volume.

Billich A, Bilban M, Meisner NC, Nussbaumer P, Neubauer A, Jäger S, Auer M.

Assay Drug Dev Technol. 2004 Feb;2(1):21-30.

PMID:
15090207
50.

Fluorescence-labeled sphingosines as substrates of sphingosine kinases 1 and 2.

Ettmayer P, Billich A, Baumruker T, Mechtcheriakova D, Schmid H, Nussbaumer P.

Bioorg Med Chem Lett. 2004 Mar 22;14(6):1555-8.

PMID:
15006402

Supplemental Content

Loading ...
Support Center